Alder Biopharmaceuticals (ALDR) Stock Price, News & Analysis

Company Overview

Alder BioPharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine. It also develops ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 for migraine prevention; and Clazakizumab, a mAb inhibiting the pro-inflammatory cytokine interleukin-6 that has completed two Phase 2b clinical trials. The company has strategic collaboration with CSL Limited for the development of clazakizumab as a therapeutic option for solid organ transplant rejection. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.

Key Stats

• Today's Range: $18.88 to $18.88
• 50-Day Range: $18.88 to $18.88
• 52-Week Range: $8.39 to $19.12
• Volume: N/A
• Average Volume: 5.12 million shs
• Market Capitalization: $1.58 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ALDR Stock Analysis - Frequently Asked Questions

How were Alder Biopharmaceuticals' earnings last quarter?

Alder Biopharmaceuticals Inc (NASDAQ:ALDR) released its quarterly earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($1.04) EPS for the quarter, beating the consensus estimate of ($1.05) by $0.01.

What other stocks do shareholders of Alder Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Alder Biopharmaceuticals investors own include Bristol-Myers Squibb (BMY), (CPXX) (CPXX), NVIDIA (NVDA), Celldex Therapeutics (CLDX), Meta Platforms (META), Gilead Sciences (GILD) and Micron Technology (MU).

Company Calendar

• Last Earnings: 8/07/2018
• Today: 5/22/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ALDR
• CIK: 1423824
• Web: www.alderbio.com
• Phone: 425-205-2900
• Fax: N/A
• Employees: 202
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($4.87)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-296,430,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -226.13%
• Return on Assets: -66.86%

Debt

• Debt-to-Equity Ratio: 1.74
• Current Ratio: 8.94
• Quick Ratio: 8.94

Sales & Book Value

• Annual Sales: $1.62 million
• Price / Sales: 977.10
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.61 per share
• Price / Book: 11.73

Miscellaneous

• Outstanding Shares: 83,840,000
• Free Float: N/A
• Market Cap: $1.58 billion
• Optionable: Optionable
• Beta: 2.64